B03XA01|Erythropoietin/Epoetin beta/|BH049|NEORECORMON|solution for injection, pre-filled syringe|10000|IU|6|60000|Roche Registration Limited,United Kingdom|502.78|2|1|0|C|8| B03XA01|Epoetin alfa|BH050|Binocrit|sol.inj. in pre-filled syr.|10000 IU/1 ml|IU|6|60000|Sandoz GmbH, Austria|502.78|2|1|0|C|8| B02BX04|Romiplostim|BH055|NPLATE|powder and solvent for sol. for inj.|250|mcg|1|250|Amgen Europe B.V., Холандия|1213.92|3|1|0|C|| B03XA01|Erythropoietin /Epoetin zeta/|BH056|Retacrit|solution for injection, pre-filled syringe|10000|IU|6|60000|Hospira UK Ltd|502.78|2|1|0|C|8| B03XA02|darbepoetin alfa|BH057|Aranesp|solution for injection prefilled syringe with needle guard|300|mcg/0,6 ml|1|300|Amgen Europe B.V., Netherlands|866.47|3|1|0|C|8| B03XA02|darbepoetin alfa|BH058|Aranesp|Solution for injection pre-filled syringe with needle guard|150|mcg/0,3 ml|1|150|Amgen Europe B.V., Netherlands|433.17|3|1|0|C|8| B03XA03|Methoxy polyethylene glycol-epoetin beta|BH081|MIRCERA|solution for injection, pre-filled syringe|150|mcg/ 0,3ml|1|150|Roche Registration Ltd,UK|487.37|3|1|0|C|| B02BX05|Eltrombopag|BH085|REVOLADE|film-coated tablet|25|mg|28|700|Novartis Europharm Ltd.,UK|1910.1|4|0|0|C|3| B02BX05|Eltrombopag|BH086|REVOLADE|film-coated tabl.|50|mg|28|1400|Novartis Europharm Ltd.,UK|3820.19|4|0|0|C|3| H02AB02|Dexamethasone|HH003|Dexamethasone Sopharma|sol. inj.|8|mg|10|80|Софарма АД, България|7.92|1|0|0|C|2| H02AB02|Dexamethasone|HH005|Dexamethasone Sopharma|sol. inj.|4|mg|10|40|Софарма АД|3.96|1|0|0|C|2| H02AB02|Dexamethasone|HH006|Dexamethasone KRKA|sol. inj.|4|mg|25|100|KRKA d.d, Slovenia|9.9|1|0|0|C|2| H01CB02|Octreotide|HH007|Sandostatin LAR|powder for inf.|20|mg|1|20|Novartis Pharma GmbH, Germany|1018.31|2|1|0|C|7| H01CB02|Octreotide|HH008|Sandostatin LAR|powder for inf.|30|mg|1|30|Novartis Pharma GmbH, Germany|1527.65|2|1|0|C|7| J06BA02|Immunoglobulin Human Normal|JH001|OCTAGAM 10%|solution for infusion|100 mg/ml - 20 ml|mg|1|2000|Octapharma (IP) Ltd, Великобритания;|182.96|1|4|0|C|1| J06BA02|Normal Human Immunoglobulin (IVI g)|JH002|Privigen|solution for infusion|100 mg/ml - 25 ml|mg|1|2500|CSL Behring GmbH, Гемания|228.7|1|4|0|C|1| J06BA02|Immunoglobulin Human Normal|JH003|OCTAGAM 10%|solution for infusion|100 mg/ml - 50 ml|mg|1|5000|Octapharma (IP) Ltd, Великобритания;|457.4|1|4|0|C|1| J06BA02|Normal Human Immunoglobulin (IVI g)|JH004|Privigen|solution for infusion|100 mg/ml - 50 ml|mg|1|5000|CSL Behring GmbH, Гемания|457.4|1|4|0|C|1| J06BA02|Normal Human Immunoglobulin (IVI g)|JH006|Privigen|solution for infusion|100 mg/ml - 100 ml|mg|1|10000|CSL Behring GmbH, Гемания|914.82|1|4|0|C|1| J06BA02|Human normal immunoglobulin (ІVІ g)|JH008|Intratect|solution for infusion|50g/l - 20 ml|mg|1|1000|Biotest Pharma GmbH, Германия|51.42|1|4|0|C|1| J06BA02|Human normal immunoglobulin (ІVІ g)|JH009|Intratect|solution for infusion|50g/l - 50 ml|mg|1|2500|Biotest Pharma GmbH, Германия|128.55|1|4|0|C|1| J06BA02|Human normal immunoglobulin (ІVІ g)|JH010|Intratect|solution for infusion|50g/l - 100 ml|mg|1|5000|Biotest Pharma GmbH, Германия|257.1|1|4|0|C|1| J06BA02|Human normal immunoglobulin (ІVІ g)|JH011|Intratect|solution for infusion|50g/l - 200 ml|mg|1|10000|Biotest Pharma GmbH, Германия|514.2|1|4|0|C|1| L01DB03|Epirubicin|LH004|Farmorubicin PFS|sol. for inj.|2 mg/ml - 25 ml|mg|1|50|Pfizer Enterprises SARL, Luxembourg|43.33|1|4|0|C|| L01BC01|Cytarabine|LH005|ALEXAN|solution for injection|50 mg/ ml - 20 ml|mg|1|1000|Ebewe Pharma Ges.m.b.H. N.fg. KG, Austria|37.64|1|4|0|C|| L01DB03|Epirubicin|LH015|"EPIRUBICIN ""EBEWE"""|concentrate for solution for injection/ infusion|2 mg/ml- 25 ml|mg|1|50|Ebewe Pharma Ges.m.b.H. N.fg. KG, Austria|43.33|1|4|0|C|| L01CD01|Paclitaxel|LH017|Sindaxel|Concentrate for solution for infusion|6 mg/ml - 50 ml|mg|1|300|Актавис ЕАД, България|66.05|1|4|0|C|| L01DB03|Epirubicin|LH024|EPISINDAN|solution for infusion|2 mg/ml - 50 ml|mg|1|100|Actavis Group PTC ehf, Исландия|86.66|1|4|0|C|| L01CD01|Paclitaxel|LH030|"Paclitaxel ""Ebewe"""|concentrate for solution for infusion|6 mg/ml - 16,7 ml|mg|1|100.2|Ebewe Pharma Ges.m.b.H. N.fg. KG, Austria|22.02|1|4|0|C|| L01CD01|Paclitaxel|LH035|PACLITAXEL KABI|concentrate for solution for infusion|6 mg/ml - 5 ml|mg|1|30|Фрезениус Каби България ЕООД|6.61|1|4|0|C|| L01CD01|Paclitaxel|LH037|PACLITAXEL KABI|concentrate for solution for infusion|6 mg/ml - 16,7 ml|mg|1|100.2|Фрезениус Каби България ЕООД|22.02|1|4|0|C|| L01CD01|Paclitaxel|LH043|PACLITAXEL KABI|concentrate for solution for infusion|6 mg/ml - 50 ml|mg|1|300|Фрезениус Каби България ЕООД|66.05|1|4|0|C|| L01CD01|Paclitaxel|LH046|Paclitaxel Accord|concentrate for solution for infusion|6 mg/ml - 50 ml|mg|1|300|Accord Healthcare Limited, UK|66.05|1|4|0|C|| L01DB06|Idarubicin|LH047|ZAVEDOS|powder for sol. for inf.|5 mg|mg|1|5|Pfizer Enterprises SARL, Luxembourg|53.88|1|4|0|C|| L01CA01|Vinblastine|LH057|Cytoblastin|solution for injection|1 mg/ml - 10 ml|mg|1|10|Cipla (UK) Ltd, UK|19.55|1|4|0|C|8| L01DB06|Idarubicin|LH065|ZAVEDOS|powder for sol. for inf.|10 mg|mg|1|10|Pfizer Enterprises SARL, Luxembourg|107.76|1|4|0|C|| L01CA02|Vincristine|LH066|Cytocristin|solution for injection|1 mg/ml - 1 ml|mg|1|1|Cipla (UK) Ltd, UK|78.82|1|4|0|C|8| L01CA04|Vinorelbine|LH073|Vinorelbin Actavis|concentrate for solution for infusion|50|mg|1|50|Актавис ЕАД, България|62.39|1|4|0|C|8| L01DB07|Mitoxantrone|LH075|MITOXANTRON EBEWE|concentrate for solution for infusion|2 mg/ml - 10 ml|mg|1|20|Ebewe Pharma Ges.m.b.H. N.fg. KG, Austria|62.51|1|4|0|C|7| L01CA04|Vinorelbine|LH078|"VINORELBIN ""EBEWE"" "|concentrate for solution for infusion|10 mg/ml - 5 ml|mg|1|50|Ebewe Pharma Ges.m.b.H. N.fg. KG, Austria|62.39|1|4|0|C|8| L01CB01|Etoposide|LH083|ETOSID|Solution for infusion|20 mg/ml - 5 ml|mg|1|100|Cipla (UK) Ltd., Обединено Кралство|64.86|1|4|0|C|| L01XA01|Cisplatin|LH109|Cisplatin Accord|concentrate for solution for infusion|1 mg/ml - 50 ml|mg|1|50|Accord Healthcare Limited, UK|10.72|1|4|0|C|| L01XA02|Carboplatin|LH113|CARBOPLATIN EBEWE|Concentrate for solution for infusion|10 mg/ml-15 ml|mg|1|150|Ebewe Pharma GmbH. N.fg. KG,, Австрия|22.39|1|4|0|C|| L01BB06|Clofarabine|LH117|EVOLTRA|concentrate for sol. for inf.|1 mg/ml - 20 ml|mg|1|20|Genzyme Europe BV, Холандия|3196.08|1|4|0|C|| L01BB07|Nelarabine|LH119|Atriance|sol. for inf.|5 mg/ml - 50 ml|mg|6|1500|Novartis Europharm Ltd, UK|3783.6|1|4|0|C|| L01BC01|Liposomal Cytarabine|LH121|DepoCyte|suspention for injection|50|mg|1|50|Pacira Ltd, MG House, Rumbolds Hill, Midhurst, West Sussex, GU29 9BY, England|3273.65|1|4|0|C|| L03AA02|Filgrastim|LH123|NIVESTIM|solution for injection/ infusion in pre-filled syringe|30 MIU/ 0,5 ml|mg|5|1.5|Hospira UK Limited, UK|233.12|2|1|0|C|7| L01XA02|Carboplatin|LH127|Carboplatin Actavis|concentrate for solution for infusion|10 mg/ml - 15 ml|mg|1|150|Actavis Group PTC ehf, Исландия|22.39|1|4|0|C|| L03AA02|Filgrastim|LH128|Zarzio|solution for injection or infusion in pre-filled syr.|30 MU/ 0,5 ml|mg|5|1.5|Sandoz GmbH, Austria|233.12|2|1|0|C|7| L01XE07|Lapatinib|LH133|TYVERB|film-coated tablets, bottle|250|mg|84|21000|Novartis Europharm Ltd, UK|2375.11|4|0|0|C|3| L01XE07|Lapatinib|LH137|TYVERB|film-coated tablets, bottle|250|mg|140|35000|Novartis Europharm Limited, United Kingdom|3958.52|4|0|0|C|3| L01XE08|Nilotinib|LH139|Tasigna|hard capsules|200|mg|28|5600|Novartis Europharm Limited, UK|1691.7|4|0|0|C|3| L01XE08|Nilotinib|LH140|Tasigna|hard capsules|150|mg|28|4200|Novartis Europharm Limited, UK|1268.78|4|0|0|C|3| L03AB04|Interferon alfa-2a|LH151|Roferon-A|solution for injection pre-filled syringe + needle|3 MIU|MU|1|3|Рош България ЕООД|23.94|3|1|0|C|8| L01XC02|Rituximab|LH154|MabThera|concentrate for sol. for inf.|100|mg/10ml|2|200|Roche Registration Ltd, UK|718.29|1|4|0|C|| L01XC02|Rituximab|LH155|MabThera|concentrate for sol. for inf.|500|mg/50ml|1|500|Roche Registration Ltd, UK|1795.72|1|4|0|C|| L01XC03|Trastuzumab|LH156|Herceptin|powder for concentrate for solution for infusion|150|mg|1|150|Roche Registration LimitedUnited Kingdom|1131.52|1|4|0|C|| L01XE09|Temsirolimus|LH158|TORISEL|Concentrate and diluent for sol. for inf.|30 mg (concentrate: 1.2 ml; diluent: 1.8 )|mg|1|30|Pfizer Ltd. UK|1651.09|1|4|0|C|| L01XC06|Cetuximab|LH160|ERBITUX|solution for infusion|5 mg/ml - 20 ml|mg|1|100|Merck KGaA, Германия|386.6|1|4|0|C|7| L01XC07|Bevacizumab|LH161|Avastin|concentrate for solution for infusion|25 mg/ml-4 ml|mg|1|100|Roche Registration LimitedUnited Kingdom|548.6|1|4|0|C|8| L01XE10|Everolimus|LH162|Afinitor|tabl.|5|mg|30|150|Novartis Europharm Limited, UK|3484.13|4|0|0|C|3| L01XC07|Bevacizumab|LH163|Avastin|concentrate for solution for infusion|25 mg/ml-16 ml|mg|1|400|Roche Registration LimitedUnited Kingdom|2156.57|1|4|0|C|8| L01XE10|Everolimus|LH164|Afinitor|tablets|10|mg|30|300|Novartis Europharm Limited, UK|6968.26|4|0|0|C|3| L01XC08|Panitumumab|LH165|Vectibix|concentrate for solution for infusion|20mg/ml - 5ml|mg|1|100|Amgen Europe B.V. Холандия|805.45|1|4|0|C|8| L01XE11|Pazopanib|LH166|VOTRIENT|film. coated tabl.|200|mg|30|6000|Novartis Europharm Ltd., UK|1353.66|4|0|0|C|3| L01XE02|Gefitinib|LH167|IRESSA|film. coated tabl.|250|mg|30|7500|AstraZeneca AB, Швеция|4337.5|4|0|0|C|3| L01XE03|Erlotinib|LH168|Tarceva|film-coated tabl.|100|mg|30|3000|Roche Registration Limited, UK|1290.77|4|0|0|C|3| L01XE03|Erlotinib|LH169|Tarceva|film-coated tabl.|150|mg|30|4500|Roche Registration Limited, UK|1936.16|4|0|0|C|3| L01XE11|Pazopanib|LH170|VOTRIENT|film. coated tabl.|400|mg|60|24000|Novartis Europharm Ltd, UK|5414.57|4|0|0|C|3| L01XE04|Sunitinib|LH172|Sutent|hard caps.|12.5|mg|30|375|Pfizer Limited, UK|2333.43|4|0|0|C|3| L01XX17|Topotecan|LH175|Hycamtin|powd. for concentrate for sol. for inf.|4|mg|1|4|Novartis Europharm Ltd., UK|74.14|1|4|0|C|| L01XE04|Sunitinib|LH176|Sutent|hard capsules|25|mg|30|750|Pfizer Limited United Kingdom|4666.86|4|0|0|C|3| L01XE04|Sunitinib|LH177|Sutent|hard caps.|50|mg|30|1500|Pfizer Limited, UK|9333.73|4|0|0|C|3| L01XE05|Sorafenib|LH179|Nexavar|film coated tabl.|200|mg|112|22400|Bayer AG, Germany|6604.8|4|0|0|C|3| L01XX17|Topotecan|LH180|POTACTASOL|powder for concentrate for solution for infusion|4|mg|1|4|Actavis Group PTC ehf., Исландия|74.14|1|4|0|C|| L01XE06|Dasatinib|LH181|Sprycel|film-coated tablets|50|mg|60|3000|Bristol-Myers Squibb Pharma EEIG, UK|6731.71|4|0|0|C|3| L01XX17|Topotecan|LH184|Hycamtin|caps. hard|1|mg|10|10|Novartis Europharm Limited, United Kingdom|569.48|4|0|0|C|3| L04AX03|Methotrexate|LH187|"METHOTREXATE ""EBEWE"""|concentrate for solution for infusion|100 mg/ml - 10 ml|mg|1|1000|Ebewe Pharma Ges.m.b.H. N.fg. KG, Austria|32.99|1|4|0|C|| L01XX19|Irinotecan|LH196|Irinotekan Actavis|concentrate for solution for injection|20 mg/ml - 5 ml|mg|1|100|Актавис ЕАД, България|52.61|1|4|0|C|| L01XX23|Mitotane|LH202|Lysodren|tabl.|500|mg|100|50000|Laboratorie HRA Pharma, France|1151.3|4|0|0|C|3| L01XE01|Imatinib|LH203|Glivec|film-coated tablets|100|mg|120|12000|Novartis Europharm Limited, UK|2523.29|4|0|0|C|3| L01XX32|Bortezomib|LH204|Velcade|powder for solution for injection|3.5|mg|1|3.5|Janssen Cilag International N.V., Belgium|1010.69|1|4|0|C|| L03AX16|Plerixafor|LH218|Mozobil|solution for injection|20 mg/ml - 1,2 ml|mg|1|24|Genzyme Europe B.V., The Netherlands|11073.67|3|1|0|C|| L01BB05|Fludarabine phosphate|LH219|Fludarabine Actavis|powder for sol. for inj./inf.|50|mg|1|50|Actavis Group PTC enf., Iceland|12.15|1|4|0|C|| L01XA03|Oxaliplatin|LH227|Oxaliplatin-Tchaikapharma|powder for solution for infusion|100|mg|1|100|„Чайкафарма Висококачествените Лекарства“ АД”, гр.София|31.02|1|4|0|C|| L01CD02|Docetaxel|LH229|Docetaxel Accord|concentrate for sol. for inf.|20 mg/1 ml|mg|1|20|Accord Healthcare Ltd, UK|19.5|1|2|0|C|| L01CD02|Docetaxel|LH230|Docetaxel Accord|concentrate for sol. for inf.|80 mg/4 ml|mg|1|80|Accord Healthcare Ltd, UK|78|1|2|0|C|| L01XX17|Topotecan|LH233|Topotecan Accord|Concentrate for solution for infusion|1 mg/ml - 4 ml|mg|1|4|Accord Healthcare Limited, Обединено Кралство|74.14|1|4|0|C|| L03AA13|Pegfilgrastim|LH234|Neulasta|sol.for inj.|10mg/ml-0.6 ml|mg|1|6|Amgen Europe B.V., The Netherlands|1504.5|2|1|0|C|7| L01CD02|Docetaxel|LH236|Docetaxel Kabi| concentrate for sol. for inf.|80 mg/4 ml|mg|1|80|Fresenius Kabi Oncology Plc, UK|78|1|2|0|C|| L01XA03|Oxaliplatin|LH237|OXALIPLATIN ACCORD|concentrate for solution for infusion|5 mg/ml - 20 ml|mg|1|100|Аccord Healthcare Limited - Обединено кралство|31.02|1|4|0|C|| L04AD01|Ciclosporin|LH243|Sandimmun Neoral|caps. soft|25|mg|50|1250|Novartis Pharma GmbH, Germany|32.22|4|0|0|C|3| L04AD01|Ciclosporin|LH244|Sandimmun Neoral|caps. soft|50|mg|50|2500|Novartis Pharma GmbH, Germany|64.44|4|0|0|C|3| L04AD01|Ciclosporin|LH253|Sandimmun Neoral|oral solution|100 mg/ml - 50 ml|mg|1|5000|Novartis Pharma GmbH, Germany|136.69|4|0|0|C|3| L01AX03|Temozolomide|LH256|Temodal|hard caps. in individual sachet|100|mg|5|500|Merck Sharp & Dohme Ltd, UK|133.49|4|0|0|C|3| L01BC05|Gemcitabine|LH257|Gembin|concentrate for solution for infusion|40 mg/ml - 5 ml|mg|1|200|Actavis Group PTC enf., Iceland|7.82|1|4|0|C|8| L01BC05|Gemcitabine|LH258|Gembin|concentrate for solution for infusion|40 mg/ml - 25 ml|mg|1|1000|Actavis Group PTC enf., Iceland|39.1|1|4|0|C|8| L01BC05|Gemcitabine|LH260|GEMCITABINE ACCORD|concentrate for solution for infusion|100 mg/ml-10 ml|mg|1|1000|Accord Healtcare Limited, UK|39.1|1|4|0|C|8| L01XA03|Oxaliplatin|LH261|Oxaliplatin Actavis|concentrate for solution for infusion|5 mg/ml - 20 ml|mg|1|100|Actavis Group PTC ehf., Iceland|31.02|1|4|0|C|| L01XA03|Oxaliplatin|LH262|Oxaliplatin Actavis|concentrate for solution for infusion|5 mg/ml - 10 ml|mg|1|50|Actavis Group PTC ehf., Iceland|15.51|1|4|0|C|| L01XA03|Oxaliplatin|LH265|Oxaliplatin Aq Vida|concentrate for solution for infusion|5 mg/ml - 10 ml|mg|1|50|AqVida GmbH Германия|15.51|1|4|0|C|| L01XE01|Imatinib|LH270|Imakrebin|film-coated tabl.|100|mg|120|12000|Alvogen IPCO, Люксембург|202.06|4|0|0|C|3| L01AA09|Bendamustine hydrochloride|LH272|Levact|powder for concentrate for solution for infusion|100 mg|mg|5|500|Astellas Pharma GmbH, Germany|1525.67|1|4|0|C|6| L01AX03|Temozolomide|LH273|Blastomat|hard caps.|100|mg|5|500|Alvogen IPCo.SARL Люксембург|133.49|4|0|0|C|3| L01CD04|Cabazitaxel|LH274|Jevtana|concentrate and solvent for solution for infusion|60|mg|1|60|Sanofi Aventis Groupe, Франция|7493.05|1|4|0|C|| L01DB01|Doxorubicin|LH275|Doxorubicin Accord|concentrate for solution for infusion|2 mg/ml-25 ml|mg|1|50|Accord Healthcare Limited Обединено кралство|17.75|1|3|0|C|7| L02BX03|Abiraterone acetate|LH277|Zytiga|tabl.|250|mg|120|30000|Janssen-Cilag International NV, Белгия|6547.02|4|0|0|C|3| L01XE01|Imatinib|LH278|Glivec|film-coated tabl.|100|mg|120|12000|Novartis Europharm Limited, UK|202.06|4|0|0|C|3| L01BC05|Gemcitabine|LH279|GEMCIT|powder for solution for infusion|38 mg/ml 2 000 mg, 100 ml|mg|1|2000|Фрезениус Каби България ЕООД|78.2|1|4|0|C|8| L01DB01|Doxorubicin hydrochloride|LH281|Myocet|powder, dispersion and concentrate for dispersion for infusion|50|mg|2|100|Teva B.V., Холандия|2062.01|1|2|0|C|7| L01XE01|Imatinib|LH285|Imatinib Accord|film-coated tablets|100|mg|120|12000|Accord Healthcare Limited, UK|202.06|4|0|0|C|3| L01BC01|Cytarabine|LH288|Cytarabine Accord|solution for injection or infusion|100 mg/ ml - 10 ml|mg|1|1000|Accord Healthcare Limited,UK|31.92|1|4|0|C|| L01BC06|Capecitabine|LH291|Capecitabine Accord|film-coated tabl.|500|mg|120|60000|Accord Healthcare Limited, UK|92.58|4|0|0|C|3| L01BC06|Capecitabine|LH295|Capecitabine Teva|film-coated tablets|500|mg|120|60000|Teva B.V. The Netherlands|92.58|4|0|0|C|3| L01BC53|tegafur/gimeracil/oteracil|LH301|Teysuno|hard caps.|15 mg/4,35 mg/11,8 mg|mg|126|3924.9|Nordic Group BV, ,Холандия|737.53|4|0|0|C|3| L01BC53|tegafur/gimeracil/oteracil|LH302|Teysuno|hard caps.|20 mg/5,8 mg/15,8 mg|mg|84|3494.4|Nordic Group BV, ,Холандия|649.9|4|0|0|C|3| L01XC11|Ipilimumab|LH303|Yervoy|concentrate for solution for infusion|5mg/ml-40 ml|mg|1|200|Bristol-Myers Squibb Pharma EEIG, Великобритания|26955.52|1|4|0|C|| L01XC11|Ipilimumab|LH304|Yervoy|concentrate for solution for infusion|5 mg/ml-10 ml|mg|1|50|Bristol-Myers Squibb Pharma EEIG, Великобритания|6738.88|1|4|0|C|| L01XE15|Vemurafenib|LH305|ZELBORAF|film-coated tabl.|240|mg|56|13440|Roche Registration Limited, UK|3488.7|4|0|0|C|3| L01XX41|Eribulin|LH306|Halaven|solution for injection|0,44 mg/ml - 2 ml|mg|1|0.88|Eisai Europe Limited, UK|748.7|1|4|0|C|| L01AX03|Temozolomide|LH307|Brastoryn|hard capsules (in bottles)|100|mg|5|500|Ромастру Трейдинг ЕООД, България|133.49|4|0|0|C|3| L01AX03|Temozolomide|LH308|Brastoryn|hard capsules (in bottles)|20|mg|5|100|Ромастру Трейдинг ЕООД, България|26.7|4|0|0|C|3| L01BC02|Fluorouracil|LH309|Fluorouracil Accord|solution for injection or infusion|50 mg/ml - 20 ml|mg|1|1000|Accord Healthcare Limited, UK|5.02|1|4|0|C|8| L01XC03|Trastuzumab|LH310|Herceptin|solution for injection|600 mg/5 ml|mg|1|600|Roche Registration Ltd, UK|3234.52|3|2|0|C|8| L04XX40|Ciclosporin|LH312|Sandimmun Neoral|caps. soft|50|mg|50|2500|Novartis Pharma GmbH, Germany|78.72|4|0|0|I|| L04XX40|Ciclosporin|LH313|Sandimmun Neoral|caps. soft|25|mg|50|1250|Novartis Pharma GmbH, Germany|39.36|4|0|0|I|| L04XX40|Ciclosporin|LH314|Sandimmun Neoral|oral. solution|5000|mg|1|5000|Novartis Pharma GmbH, Germany|136.74|4|0|0|I|| L04AA06|Mycophenolic acid/Mycophenolate mofetil|LH315|CellCept|caps. hard|250|mg|100|25000|Roche Registration Ltd, UK|85.68|4|0|0|I|| L01CD01|Paclitaxel|LH317|Paclitaxel Accord|concentrate for sol. for inf.|6mg/ml - 16,7 ml|mg|1|100.2|Accord Healthcare Ltd, UK|22.02|1|4|0|C|| L01CD02|Docetaxel|LH318|Tolnexa|concentrate for sol. for inf.|20 mg/ml - 1 ml|mg|1|20|KRKA, d. d.|19.5|1|2|0|C|| L01CD02|Docetaxel|LH319|Tolnexa|concentrate for sol. for inf.|20 mg/ml - 4 ml|mg|1|80|KRKA, d. d.|78|1|2|0|C|| L01XC02|Rituximab|LH320|MabThera|sol. for inj.|1400mg/11.7 ml|mg|1|1400|Roche Registration Ltd, UK|3462.9|3|1|0|C|| L01XX35|Anagrelide|LH321|THROMBOREDUCTIN|hard caps.|0.5|mg|100|50|AOP Orphan Pharmaceuticals AG, Austria|683.08|4|0|0|C|3| L01XE01|Imatinib|LH324|Meaxin|film-coated tabl.|100|mg|120|12000|KRKA, d. d.|202.06|4|0|0|C|3| L01BC06|Capecitabine|LH326|Ecansya|film-coat. tabl.|500|mg|120|60000|KRKA, d.d.|92.58|4|0|0|C|3| L01BC06|Capecitabine|LH327|Ecansya|film-coat. tabl.|150|mg|30|4500|KRKA, d.d.|6.93|4|0|0|C|3| L01BC06|Capecitabine|LH328|Ecansya|film-coat. tabl.|500|mg|30|15000|KRKA, d.d.|23.1|4|0|0|C|3| L01BC06|Capecitabine|LH329|Ecansya|film-coat. tabl.|150|mg|60|9000|KRKA, d.d.|13.86|4|0|0|C|3| L01CD02|Docetaxel|LH331|Tolnexa|concentrate for sol. for inf.|20 mg/ml - 8 ml|mg|1|160|KRKA, d.d.|156|1|2|0|C|| L01DB03|Epirubicin hydrochloride|LH332|Episindan|sol. for inj.|2 mg/ml - 25 ml|mg|1|50|Actavis Group PTC ehf|43.33|1|4|0|C|| L01XC12|Brentuximab vedotin|LH334|Adcetris|powder for concentrate for sol. for inf.|50|mg|1|50|Takeda Pharma A/S, Дания|6962.63|1|2|0|C|| L01XC13|Pertuzumab|LH335|Perjeta|concentrate for solution for infusion|420|mg|1|420|Roche Registration Ltd, UK|6003.9|1|2|0|C|8| L01XE13|Afatinib|LH336|Giotrif|film-coated tablets|30|mg|28|840|Boehringer Ingelheim International GmbH, Germany|3009.74|4|0|0|C|3| L01XE13|Afatinib|LH337|Giotrif|film-coated tablets|40|mg|28|1120|Boehringer Ingelheim International GmbH, Germany|4012.99|4|0|0|C|3| L01XE16|Crizotinib|LH338|Xalkori|hard capsules|250|mg|60|15000|Pfizer Ltd, UK|10574.09|4|0|0|C|3| L01XE17|Axitinib|LH339|Inlyta|film. coated tabl.|5|mg|56|280|Pfizer Ltd, UK|7477.12|4|0|0|C|3| L01XE18|Ruxolitinib|LH340|Jakavi|tabl.|5|mg|56|280|Novartis Europharm Ltd.|3545|4|0|0|C|3| L01XX44|Aflibercept|LH341|Zaltrap|concentrate for sol. for inf.|25 mg/ml - 8 ml|mg|1|200|Sanofi-Aventis Groupe, France|1369.6|1|3|0|C|8| L01XX44|Aflibercept|LH342|Zaltrap|concentrate for sol. for inf.|25 mg/ml - 4 ml|mg|1|100|Sanofi-Aventis Groupe, France|684.8|1|3|0|C|8| L02BB04|Enzalutamide|LH343|Xtandi|soft capsules|40|mg|112|4480|Astellas Pharma Europe B.V., Нидерландия|6315.07|4|0|0|C|3| L03AA14|Lipegfilgrastim|LH344|Lonquex|solution for injection in pre-filled syringe|6mg/0,6ml|mg|1|6|UAB Sicor Biotech, Литва|1630.91|3|1|0|C|7| L01AA09|Bendamustine hydrochloride|LH348|Bendamustine Actavis|Powder for concentrate for solution for infusion|2.5mg/ml|mg|1|100|Actavis Group PTC ehf., Исландия|305.13|1|4|0|C|6| L01XX32|Bortezomib|LH349|Vortemyel|powder for solution for injection|3.5|mg|1|3.5|Alvogen IPCo S.ar.l, Люксембург|1010.69|1|4|0|C|| L01BC06|Capecitabine|LH353|Xalvobin|film-coat tabl.|500|mg|120|60000|Alvogen IPCo.S.ar.I|92.58|4|0|0|C|3| L01XX32|Bortezomib|LH354|Bortezomib Actavis|powd. for sol. for inj.|3.5|mg|1|3.5|Actavis Group PTC ehf.|1010.69|1|4|0|C|| L01BC07|Azacitidin|LH355|Vidaza|powd. for susp. for inj.|25mg/ml|mg|1|100|Celgene Europe Ltd., UK|722.36|3|1|0|C|| L01XC10|Ofatumumab|LH356|Arzerra|concentrate for solution for infusion|100 mg (20 mg/ml), 5 ml|mg|3|300|Novartis Europharm Ltd., UK|1401.54|1|4|0|C|| L01XC10|Ofatumumab|LH357|Arzerra|concentrate for solution for infusion|1000 mg (20 mg/ml), 50 ml|mg|1|1000|Novartis Europharm Ltd., UK|4671.79|1|4|0|C|| L01XC14|Trastuzumab emtansine|LH358|Kadcyla|powder for concentrate for sol. for inf.|100 mg/5 ml|mg|1|100|Roche Registration Ltd., UK|3624.25|1|2|0|C|| L01XC14|Trastuzumab emtansine|LH359|Kadcyla|powder for concentrate for solution for infusion|160 mg/8 ml|mg|1|160|Roche Registration Ltd., UK|5798.8|1|2|0|C|| L01XE12|Vandetanib|LH360|Caprelsa|film-coated tabl.|100|mg|30|3000|AstraZeneca AB.|3194.79|4|0|0|C|3| L01XE12|Vandetanib|LH361|Caprelsa|film-coated tabl.|300|mg|30|9000|AstraZeneca AB.|9584.36|4|0|0|C|3| L01XE14|Bosutinib|LH362|Bosulif|film-coated tabl.|100|mg|28|2800|Pfizer Ltd., UK|1448.15|4|0|0|C|3| L01XE14|Bosutinib|LH363|Bosulif|film-coated tabl.|500|mg|28|14000|Pfizer Ltd., UK|7240.75|4|0|0|C|3| L01XE23|Dabrafenib|LH364|Tafinlar|caps. hard|75|mg|120|9000|Novartis Europharm Ltd., UK|12920.48|4|0|0|C|3| L01XX43|Vismodegib|LH365|Erivedge|caps. hard|150|mg|28|4200|Roche Registration Ltd, UK|9737.95|4|0|0|C|3| L01AA02|Chlorambucil|LH366|Leukeran|film-coated tablet|2|mg|25|50|Aspen Pharma Trading Ltd, Ireland|119.77|4|0|0|C|3| L01BA04|Pemetrexed|LH367|Pemetrexed Sandoz|powd. for concentrate for sol. for inf.|500|mg|1|500|Sandoz GmbH, Austria|1063.03|1|2|0|C|7| L01BB02|Mercaptopurine|LH368|Puri-Nethol|tabl.|50|mg|25|1250|Aspen Pharma Trading Ltd, Ireland|126.9|4|0|0|C|3| L01XC18|РEMBROLIZUMAB|LH369|Keytruda|powd. for concentrate for sol. for inf.|50|mg|1|50|Merck Sharp & Dohme Ltd. UK|3810.77|1|2|0|C|| L01XC21|Ramucirumab|LH370|Cyramza|concentrate for sol. for inf.|10 mg/ml – 10 ml|mg|2|200|Eli Lilly Nederland B.V.|2376.11|1|3|0|C|| L01BA04|Pemetrexed|LH372|Pemetrexed Alvogen|powd. for concentrate for sol. for inf.|500|mg|1|500|Alvogen IPCo.S.ar.l, Люксембург|1063.03|1|2|0|C|7| L01BA04|Pemetrexed|LH375|Armisarte|concentrate for sol. for inf.|25 mg/ml - 20 ml|mg|1|500|Actavis Group PTC ehf., Исландия|1063.03|1|2|0|C|7| L01BA04|Pemetrexed|LH376|Armisarte|concentrate for sol. for inf.|25 mg/ml - 40 ml|mg|1|1000|Actavis Group PTC ehf., Исландия|2126.06|1|2|0|C|7| L01XE01|Imatinib|LH377|Imatinib Actavis Group|film-coated tabl.|100|mg|120|12000|Actavis Group PTC ehf., Исландия|202.06|4|0|0|C|3| L01AX03|Temozolomide|LH378|Temozolomide Sandoz|capsule, hard|100|mg|20|2000|Sandoz GmbH, Австрия|533.96|4|0|0|C|3| L01AX03|Temozolomide|LH379|Temozolomide Accord|capsule, hard (in bottles)|100|mg|5|500|Accord Healthcare Limited, UK|133.49|4|0|0|C|3| L01XX32|Bortezomib|LH380|Bortezomib Accord|Powder for solution for injection|3.5|mg|1|3.5|Accord Healthcare Limited, UK|1010.69|1|4|0|C|| L01BC02|Fluorouracil|LH382|5-FLUOROURACIL EBEWE|Concentrate for solution for injection/ infusion|50 mg/ml - 20 ml|mg|10|10000|Ebewe Pharma GmbH. N.fg. KG,, Австрия|50.2|1|4|0|C|8| L01CD02|Docetaxel|LH383|DOCETAXEL ACTAVIS|Concentrate for sol. for inf.|20 mg/ml- 8 ml|mg|1|160|Actavis Group PTC ehf., Исландия|156|1|2|0|C|| L01BA04|Pemetrexed|LH384|Pemetrexed Heaton|powder for concentrate for solution for infusion|500|mg|1|500|Heaton k.s., Чешка република|1063.03|1|2|0|C|7| L03AX03|Mycobacterium bovis BCG|LH386|CALGEVAX|Powder for suspension|11.25|mg|4|45|БУЛ БИО-НЦЗПБ ЕООД, България|149.76|1|4|0|C|6| L01BA04|Pemetrexed|LH387|Pemetrexed Accord|Powder for concentrate for solution for infusion|500|mg|1|500|Accord Healthcare Limited, UK|1063.03|1|2|0|C|7| L01BC05|Gemcitabine|LH388|Gemcitabine Actavis|Concentrate for solution for infusion|40 mg/ml – 25 ml|mg|1|1000|Actavis Group PTC ehf., Исландия|39.1|1|4|0|C|8| L01BC05|Gemcitabine|LH389|Gemcitabine Actavis|Concentrate for solution for infusion|40 mg/ml – 50 ml|mg|1|2000|Actavis Group PTC ehf., Исландия|78.2|1|4|0|C|8| L01XE27|Ibrutinib|LH390|Imbruvica|Capsule, hard|140|mg|90|12600|Janssen-Cilag International N.V., Белгия|12592.09|4|0|0|C|3| L01XX46|Olaparib|LH391|Lynparza|Capsule, hard|50|mg|448|22400|Astra Zeneca AB, Швеция|11470.34|4|0|0|C|3| L01XC18|PEMBROLIZUMAB|LH392|Keytruda|powd. for concentrate for sol. for inf.|50|mg|1|50|Merck Sharp & Dohme Ltd. UK|3810.77|1|2|0|C|| L01XE17|Axitinib|LH393|Inlyta|film coated tabl.|1|mg|56|56|Pfizer Ltd, UK|1495.42|4|0|0|C|3| L01XE03|Erlotinib|LH394|Varlota|Film coated tablet|100|mg|30|3000|Alvogen Malta Operations (ROW) Ltd., Малта|1290.77|4|0|0|C|3| L01XE03|Erlotinib|LH395|Varlota|Film coated tablet|150|mg|30|4500|Alvogen Malta Operations (ROW) Ltd., Малта|1936.16|4|0|0|C|3| L01XX32|Bortezomib|LH396|Bortezomib Sandoz|Powder for solution for injection|3.5|mg|1|3.5|Sandoz d.d., Словения|1010.69|1|4|0|C|| L01AA01|Cyclophosphamide|LH397|ENDOXAN|Powder for solution for injection|200|mg|10|2000|Екофарм Груп АД, България|51.74|1|4|0|C|7| L01AA06|Ifosfamide|LH398|HOLOXAN|Powder for solution for infusion|1000|mg|1|1000|Екофарм Груп АД, България|47.21|1|4|0|C|| L01XC18|Рembrolizumab|LH399|Keytruda|Concentrate for solution for infusion|25 mg/ml - 4 ml|mg|1|100|Merck Sharp & Dohme Ltd., Обединено Кралство|7621.54|1|2|0|C|| L01XC18|Рembrolizumab|LH400|Keytruda|Concentrate for solution for infusion|25 mg/ml - 4 ml|mg|1|100|Merck Sharp & Dohme Ltd., Обединено Кралство|7621.54|1|2|0|C|| L01XE01|Imatinib|LH401|Imatinib Teva Pharma|Film coated tablet|100|mg|120|12000|Тева Фармасютикълс България ЕООД, България|2523.29|4|0|0|C|3| L01XE01|Imatinib|LH402|Imatinib Teva Pharma|Film coated tablet|100|mg|120|12000|Тева Фармасютикълс България ЕООД, България|202.06|4|0|0|C|3| L01XE01|Imatinib|LH403|Nibix|Capsule, hard|100|mg|120|12000|Adamed Sp.z.o.o., Полша|202.06|4|0|0|C|3| L01XE03|Erlotinib|LH404|Erlotinib Sandoz|Film coated tablet|100|mg|30|3000|Sandoz d.d., Словения|1555.9|4|0|0|C|3| L01XE03|Erlotinib|LH405|Erlotinib Actavis|Film coated tablet|100|mg|30|3000|Actavis Group PTC ehf., Исландия|1290.77|4|0|0|C|3| L01XE03|Erlotinib|LH406|Erlotinib Actavis|Film coated tablet|150|mg|30|4500|Actavis Group PTC ehf., Исландия|1936.16|4|0|0|C|3| L01XE03|Erlotinib|LH427|Erlotinib Sandoz|Film coated tablet|150|mg|30|4500|Sandoz d.d., Словения|1936.16|4|0|0|C|3| M05BA06|Ibandronic acid|MH004|IBANDRONIC ACID SANDOZ|cincentrate for solution for infusion|6 mg/6 ml|mg|5|30|Sandoz d.d., Slovenia|662.15|1|4|0|C|8| M05BA08|Zoledronic acid|MH012|Zoledronic acid Actavis|concentrate for solution for infusion|4mg/5ml|mg|1|4|Actavis Group PTC enf., Исландия|22.91|1|4|0|C|| M05BA08|Zoledronic acid|MH013|Zoledronic acid Teva|concentrate for solution for infusion|4mg/5ml|mg|1|4|Teva B.V., The Netherlands|22.91|1|4|0|C|| M05BA06|Ibandronic acid|MH014|Ibandronic acid Accord|Concentrate for solution for infusion|6 mg/6 ml|mg|1|6|Accord Healthcare Limited, Обединено Кралство|132.43|1|4|0|C|8| M05BA08|Zoledronic acid|MH015|Zoledronic acid Fresenius Kabi|concentrate for solution for infusion|4mg/5ml|mg|1|4|Фрезениус Каби България ЕООД|22.91|1|4|0|C|| M05BA08|Zoledronic acid|MH016|Zoledronic acid Hospira|concentrate for solution for infusion|4mg/5ml|mg|1|4|Hospira UK Ltd., UK|22.91|1|4|0|C|| M05BX04|Denosumab|MH017|Xgeva|sol. for inj.|120 mg/1.7ml|mg|1|120|Amgen Europe BV., The Netherlands|568.8|3|1|0|C|8| M05BA08|Zoledronic acid|MH019|Zoledronic acid Sandoz|concentrate for solution for infusion|4mg/5ml|mg|1|4|Sandoz d.d, Словения|22.91|1|4|0|C|| M05BA08|Zoledronic acid|MH022|Zoledronic acid Accord|concentrate for sol. for inf.|4 mg/5 ml|mg|1|4|Accord Healthcare Ltd, UK|22.91|1|4|0|C|| N02AA01|Morphine|NO572|MORPHINE SOPHARMA sol. inj. 20 mg/ml - 1 ml x 100|sol. inj.|20mg/ml-1ml|mg|100|2000|Софарма АД, Илиенско шосе 16, 1220 София, България|144.77|2|0|1|C|| N02AA05|Oxycodone|NO580|OXYCONTIN|modified-release tabl.|20|mg|50|1000|Mundipharma Ges.m.b.H, Austria|16.98|4|0|1|C|| N02AA05|Oxycodone|NO581|OXYCONTIN|modified-release tabl.|80|mg|50|4000|Mundipharma Ges.m.b.H, Austria|67.93|4|0|1|C|| N02AA05|Oxycodone|NO582|OXYCONTIN|modified-release tabl.|10|mg|50|500|Mundipharma Ges.m.b.H, Austria|8.5|4|0|1|C|| N02AA05|Oxycodone|NO583|OXYCONTIN|modified-release tabl.|40|mg|50|2000|Mundipharma Ges.m.b.H, Austria|33.97|4|0|1|C|| N02AA55|Oxycodone hidrochloride/ Naloxone hidrochloride|NO584|TARGIN|prolonged release tablets|5mg/2.5 mg|mg|50|250|Mundipharma GmbH, Австрия|34.61|4|0|1|C|| N02AA55|Oxycodone hidrochloride/ Naloxone hidrochloride|NO585|TARGIN|prolonged release tablets|10mg/5mg|mg|50|500|Mundipharma GmbH, Австрия|69.32|4|0|1|C|| N02AA55|Oxycodone hidrochloride/ Naloxone hidrochloride|NO586|TARGIN|prolonged release tablets|20mg/10 mg|mg|50|1000|Mundipharma GmbH, Австрия|138.54|4|0|1|C|| N02AB02|Pethidine hydrochloride|NO588|LYDOL sol.for inj. 50 mg/ml- 2 ml x 10|solution for injection|50mg/ml-2ml|mg|10|1000|Софарма АД, Илиенско шосе 16, 1220 София, България|16.8|2|0|1|C|| N02AB02|Pethidine hydrochloride|NO589|LYDOL sol.for inj. 50 mg/ml- 2 ml x 50|solution for injection|50mg/ml-2 ml|mg|50|5000|Софарма АД, Илиенско шосе 16, 1220 София, България|84|2|0|1|C|| N02AB03|Fentanyl|NO590|Victanyl 75 micrograms/h transdermal patches x 5|transdermal patches|75 mcg/h|mcg|5|375|Actavis Group PTC ehf, Iceland|40.24|4|0|1|C|| N02AB03|Fentanyl|NO592|Victanyl 50 micrograms/h transdermal patches x 5|transdermal patches|50 mcg/h|mcg|5|250|Actavis Group PTC ehf, Iceland|26.83|4|0|1|C|| N02AB03|Fentanyl|NO593|Victanyl 100 micrograms/h transdermal patches x 5|transdermal patches|100 mcg/h|mcg|5|500|Actavis Group PTC ehf, Iceland|53.65|4|0|1|C|| N02AA01|Morphine|NO597|MORPHINE SOPHARMA sol. inj. 20 mg/ml - 1 ml x 10|sol. inj.|20mg/ml-1ml|mg|10|200|Софарма АД, Илиенско шосе 16, 1220 София, България|14.48|2|0|1|C|| N02AA05|Oxycodone|NO600|Oxycodone Actavis|caps. hard|10|mg|50|500|Actavis Group PTC ehf, Iceland|8.5|4|0|1|C|| N02AA05|Oxycodone|NO601|Oxycodone Actavis|caps. hard|20|mg|50|1000|Actavis Group PTC ehf, Iceland|16.98|4|0|1|C|| N02AA55|Oxycodone hidrochloride/ Naloxone hidrochloride|NO603|TARGIN|prolong. release tabl.|40mg/20mg| mg|100|4000|Mundipharma GmbH, Австрия|554.26|4|0|1|C|| N02AE01|Buprenorphine|NO604|Buprenorphin Actavis|transdermal patch|35 mcg/h|mcg|5|175|Actavis Group PTC ehf, Iceland|32.2|4|0|1|C|| N02AE01|Buprenorphine|NO605|Buprenorphin Actavis|transdermal patch|52,5 mcg/h|mcg|5|261|Actavis Group PTC ehf, Iceland|48.3|4|0|1|C|| N02AE01|Buprenorphine|NO606|Buprenorphin Actavis|transdermal patch|70 mcg/h|mcg|5|350|Actavis Group PTC ehf, Iceland|64.4|4|0|1|C|| N02AA01|Morphine|NO610|Doltard|prolong release tabl.|30|mg|100|3000|Takeda Pharma A/S, Denmark|21.37|4|0|1|C|| N02AX02|Tramadol|NO611|TRAMADOL STADA|sol. for inj.| 50 mg/ml - 2 ml|mg|5|500|Stada Arzenimittel AG|4.88|2|0|1|C|| N02AA05|Oxycodone hydrochloride|NO612|Oxycodone Actavis|prolonged-release tabl.|10|mg|50|500|Actavis Group PTC ehf., Исландия|8.5|4|0|1|C|| N02AA05|Oxycodone hydrochloride|NO613|Oxycodone Actavis|prolonged-release tabl.|20|mg|50|1000|Actavis Group PTC ehf., Исландия|16.98|4|0|1|C|| N02AA05|Oxycodone hydrochloride|NO614|Oxycodone Actavis|prolonged-release tabl.|40|mg|50|2000|Actavis Group PTC ehf., Исландия|33.97|4|0|1|C|| N02AA05|Oxycodone hydrochloride|NO615|Oxylan|prolonged- release tabl.|5|mg|50|250|G.L.Pharma GmbH., Австрия|4.24|4|0|1|C|| N02AA05|Oxycodone|NO616|Oxylan|prolong release tabl.|10|mg|50|500|G. L. Pharma GmbH, Austria|8.5|4|0|1|C|| N02AA05|Oxycodone hydrochloride|NO617|Oxylan|prolonged- release tablets|20|mg|50|1000|G.L.Pharma GmbH., Австрия|16.98|4|0|1|C|| N02AA05|Oxycodone hydrochloride|NO618|Oxylan|prolonged- release tablets|40|mg|50|2000|G.L.Pharma GmbH., Австрия|33.97|4|0|1|C|| N02AA05|Oxycodone hydrochloride|NO619|Oxylan|prolonged- release tablets|80|mg|50|4000|G.L.Pharma GmbH., Австрия|67.93|4|0|1|C|| N02AX52|Tramadol/Paracetamol|NO620|Paratramol|film-coated tabl.|37,5mg/325mg|mg|2|3625|Pharmaceutical Works POLPHARMA S.A.|2.92|4|0|1|C|| N02AB03|Fentanyl|NO621|Vellofent|Sublingual tablet|133 mcg|mcg|4|532|Анджелини Фарма България ЕООД, България|51.55|4|0|1|C|| N02AA08|Dihydrocodeine|NP414|DHC Continus|modified-release tablets|90|mg|50|4500|Mundipharma Ges.m.b.H., Vienna, Austria|37.45|4|0|1|C|| N02AX02|Tramadol|NP415|TRAMALGIN sol.for inj. 50 mg/ml-2 ml x10|sol.for inj.|50 mg/ml-2 ml|mg|10|1000|Софарма АД|9.76|2|0|1|C|| N02AX02|Tramadol|NP419|TRAMADOL STADA|caps. hard|50|mg|30|1500|Stada Arzenimittel AG|4.28|4|0|1|C|| N02AX02|Tramadol hydrochloride|NP420|TRAMALGIN|caps. hard|50|mg|20|1000|УНИФАРМ АД|2.85|4|0|1|C|| V03AC02|Deferiprone|VH008|Ferriprox|film-coated tabl.|500|mg|100|50000|Apotex Europe B.V., The Netherlands|385.03|4|0|0|C|3| V03AC01|Deferoxamine|VH009|Desferal|powder for solution for injection|500|mg|10|5000|Novartis Pharma GmbH, Germany|53.58|1|4|0|C|1| V03AC02|Deferiprone|VH010|Ferriprox|oral solution|100 mg/ml-500 ml|mg|1|50000|Apotex Europe B.V., The Netherlands|340.34|4|0|0|C|3| V03AF03|Calcium folinate|VH013|Calcium folinate Actavis|sol. for inj./inf.|10 mg/ml - 10 ml|mg|1|100|Actavis Group PTC enf., Iceland|12.04|1|0|0|C|0| V03AC03|Deferasirox|VH014|Exjade|disp.tabl.|250|mg|28|7000|Novartis Europharm Ltd., UK|694.86|4|0|0|C|3| V03AF03|Calcium folinate|VH015|Bendafolin|sol. for inj.|10 mg/ml - 100 ml|mg|1|1000|Lyomark Pharma GmbH, Germany|120.18|1|0|0|C|0| V03AF03|Calcium folinate|VH016|Bendafolin|sol. for inj.|10 mg/ml - 50 ml|mg|1|500|Lyomark Pharma GmbH, Germany|60.06|1|0|0|C|0| V03AF03|Calcium folinate|VH018|Calcium folinate Sandoz|Solution for injection/infusion|10 mg/ml-10 ml|mg|1|100|Sandoz d.d., Словения|12.04|1|0|0|C|0| V03AF03|Calcium folinate|VH019|Calcium folinate Sandoz|Solution for injection/infusion|10 mg/ml-5 ml|mg|5|250|Sandoz d.d., Словения|30.06|1|0|0|C|0|